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Catatonia is a psychomotor syndrome that not only fre-
quently occurs in the context of schizophrenia but also 
in other conditions. The neural correlates of catatonia 
remain unclear due to small-sized studies. We therefore 
compared resting-state cerebral blood flow (rCBF) and 
gray matter (GM) density between schizophrenia patients 
with current catatonia and without catatonia and healthy 
controls. We included 42 schizophrenia patients and 41 
controls. Catatonia was currently present in 15 patients 
(scoring >2 items on the Bush Francis Catatonia Rating 
Scale screening). Patients did not differ in antipsychotic 
medication or positive symptoms. We acquired whole-
brain rCBF using arterial spin labeling and GM density. 
We compared whole-brain perfusion and GM density 
over all and between the groups using 1-way ANCOVAs 
(F and T tests). We found a group effect (F test) of rCBF 
within bilateral supplementary motor area (SMA), ante-
rior cingulate cortex, dorsolateral prefrontal cortex, left 
interior parietal lobe, and cerebellum. T tests indicated 
1 cluster (SMA) to be specific to catatonia. Moreover, 
catatonia of excited and retarded types differed in SMA 
perfusion. Furthermore, increased catatonia severity 
was associated with higher perfusion in SMA. Finally, 
catatonia patients had a distinct pattern of GM density 
reduction compared to controls with prominent GM loss 
in frontal and insular cortices. SMA resting-state hyper-
perfusion is a marker of current catatonia in schizo-
phrenia. This is highly compatible with a dysregulated 
motor system in catatonia, particularly affecting premo-
tor areas. Moreover, SMA perfusion was differentially 
altered in retarded and excited catatonia subtypes, argu-
ing for distinct pathobiology.
Key words:  motor system/subthalamic nucleus/arterial 
spin labeling/SMA /retarded catatonia/cerebellum
Introduction
Catatonia has been described and termed by Karl 
Kahlbaum in 18741 as a complex syndrome of bizarre 
motor behavior, impaired volition, and vegetative abnor-
malities. This severe psychomotor syndrome is associated 
with various psychiatric disorders and medical condi-
tions and may also occur in the context of schizophrenia. 
Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-5) allows diagnosing catatonia in 
all major mood disorders, psychotic disorders, in general 
medical conditions, and as a separate entity not otherwise 
specified. In general, the symptom presentation of cata-
tonia is broad and very diverse. In addition, symptoms 
may wax and wane.2–6 Most importantly, the catatonic 
syndrome may become a live-threatening condition.7,8
Even though recent investigations demonstrated 
considerably high prevalence rates of  catatonia across 
psychiatric conditions3,4,9–13 (estimated prevalence rates: 
28% schizophrenia and 44% affective disorders),13–15 lit-
tle is known on the pathophysiology. Only few reports 
with small sample sizes explored catatonia with neuro-
imaging methods.16,17 Investigations yielded inconsistent 
results with reports of  decreased18,19 as well as increased20 
resting-state perfusion in prefrontal brain areas and the 
motor cortex. In catatonia, neural activity in the supple-
mentary motor area (SMA) and primary motor cortex 
was reduced during finger tapping tasks.17,21,22 Moreover, 
catatonic patients had reduced gamma amino butyric 
acid A (GABAA) receptor density in the primary motor 
cortex.23 Finally, the few structural neuroimaging stud-
ies (eg, cerebral computed tomography investigations) 
detected alterations in catatonia mainly in frontal corti-
cal regions and the cerebellum.19,24,25
The psychomotor symptoms of schizophrenia map 
on the cerebral motor circuit.26 Schizophrenia patients 
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with psychomotor retardation suffer from critical distur-
bances of cortico-subcortical interactions in the motor 
loop, compensated by increased premotor cortical activ-
ity.27–29 Thus, current catatonia symptoms may lead to 
increased premotor neural activity.
In this study, we aimed to compare resting-state cere-
bral blood flow (rCBF) and gray matter (GM) density 
(voxel-based morphometry [VBM]) between schizophre-
nia patients with current catatonia and without catato-
nia and healthy controls. Based on previous findings, we 
hypothesized current catatonia to be linked to increased 
neural activity, ie, hyperperfusion in premotor areas. In 
order to focus on homogeneous underlying pathology, we 
restricted the investigation to acute catatonia in the con-
text of schizophrenia spectrum disorders.
Methods
Subjects
We included 42 schizophrenia patients according to 
DSM-5 criteria, either with current catatonia or with-
out lifetime history of catatonia, and 41 healthy controls 
participants. Patients were recruited at the inpatient and 
outpatient departments of the University Hospital of 
Psychiatry, Bern. Healthy control subjects were recruited 
via advertisement and among staff  and students. Controls 
were matched for age, gender, and duration of educa-
tion. All participants were right-handed according to the 
Edinburgh Handedness Inventory.30 General exclusion 
criteria for all subjects were substance abuse or depen-
dence other than nicotine, history of motor impairments 
such as dystonia, idiopathic parkinsonism, multiple scle-
rosis or stroke, history of head trauma with concurrent 
loss of consciousness, or history of electroconvulsive 
treatment. Additional exclusion criteria for controls were 
a history of any psychiatric disorder, as well as any first-
degree relatives with schizophrenia or schizoaffective 
disorder. All participants provided written informed con-
sent. The study protocol adhered to the declaration of 
Helsinki and was approved by the local ethics committee.
All participants were interviewed with the Mini-
International Neuropsychiatric Interview (MINI).31 
Patients were further interviewed with the Comprehensive 
Assessment of Symptoms and History (CASH).32 All 
but 3 patients were on antipsychotic medication, mean 
chlorpromazine equivalents (CPZEs) were calculated 
according to Woods.33 Six patients (2 with catatonia and 
4 without) received benzodiazepines within 24 hours 
prior to magnetic resonance imaging (MRI) scanning (see 
supplementary table S1A). Diazepam equivalents (DEs) 
were calculated according to Ashton.34 In addition, we 
assessed psychopathology with the Positive And Negative 
Syndrome Scale (PANSS)35 and catatonia symptoms with 
the Bush Francis Catatonia Rating Scale (BFCRS).36  
Briefly, the BFCRS consists of 23 items (eg, mutism, 
excitement, preservation, or autonomic abnormality). The 
first 14 items constitute the BFCRS Screening Instrument 
(BFCRSI), rating presence of signs independent of sever-
ity. Presence of 2 or more BFCRSI items for more than 
24 hours indicate current catatonia.36 Catatonia severity 
rating includes all 23 items. Severity ratings for all items 
range from 0 to 3, with higher scores indicating increased 
severity. In addition to catatonia, patients had parkinso-
nian symptoms as determined by the Unified Parkinson’s 
Disease Rating Scale (UPDRS)37 motor part (table 1).
Catatonia was currently present in 15 patients (scoring 
at least at 2 items on the BFCSI for more than 24 h). Two 
groups of patients were not included in this study: first 
patients with past catatonia episodes according to the 
CASH interview and review of all case files who would 






Gender (n) Men/women Men/women Men/women χ2 df P
25/16 11/4 17/10 0.74 2 .691
M (SD) M (SD) M (SD) F/T df P
Age (y) 38.6 (13.6) 35.9 (12.7) 37.1 (10.6) 0.47 2 .762
Education (y) 14.1 (2.7) 12.0 (4.0) 14.2 (3.1) 2.81 2 .066
Number of episodes — 7.7 (8.3) 6.5 (6.9) 0.48 40 .634
DOI (mo) — 153.4 (143.9) 126.4 (127.2) 0.63 40 .533
CPZE (mg) — 461.3 (346.4) 373.6 (359.4) 0.77 40 .447
DE (mg) — 3.4 (12.9) 8.7 (28.2) −0.682 40 .499
PANSS total — 77.1 (18.9) 67.1 (16.3) 1.79 40 .080
PANSS positive — 16.0 (8.1) 17.9 (6.2) −0.86 40 .394
PANSS negative — 21.9 (6.9) 16.4 (4.1) 2.87 40 .010
BFCRS total — 8.2 (5.2) 0.0 (0.0) — — —
BFCRS screening — 5.4 (3.6) 0.0 (0.0) — — —
UPDRS III (motor part) — 15.6 (7.9) 4.4 (5.3) 5.09 36 <.001
Note: BFCRS, Bush Francis Catatonia Rating Scale; CPZE, chlorpromazine equivalence; DE, diazepam equivalent; DOI, duration of illness; 
PANSS, Positive And Negative Syndrome Scale; UPDRS, Unified Parkinson’s Disease Rating Scale. Significant values are highlighted in bold. 
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not qualify for current catatonia according to the BFCRS 
and second patients with current catatonia symptoms 
below the BFCRS threshold. Patients with catatonia 
(n = 15) and without catatonia (n = 27) did not differ in 
medication dosage (CPZEs or DEs) or positive and total 
PANSS scores (see table 1). In addition, we classified cata-
tonia patients into those with motor retardation (retarded 
catatonia: loading on “retarded” signs derived from the 
BFCSI: immobility/stupor, mutism, staring, echopraxia/
echolalia, rigidity, negativism, and withdrawal) and those 
with motor excitation (excited catatonia: loading on 
“excited” signs on the BFCSI: excitement, grimacing, ste-
reotypy, and verbigeration).10 Full list of catatonia symp-
toms presented is given in the supplementary table S1B.
Neuroimaging
Imaging was performed on a 3T MRI scanner (Siemens 
Magnetom Trio; Siemens Medical Solutions, Erlangen, 
Germany) with a 12-channel radio frequency head coil 
for signal reception. 3D-T1-weighted (Modified Driven 
Equilibrium Fourier Transform [MDEFT] pulse sequence) 
images for each subject have been obtained, providing 176 
sagittal slices with 256 × 256 matrix points with a noncu-
bic field of view (FOV) of 256  mm, yielding a nominal 
isotopic resolution of 1 mm3 (ie, 1 mm × 1 mm × 1 mm). 
Further scan parameters for the anatomical data were 
7.92 ms repetition time (TR), 2.48 ms echo time (TE) and 
a flip angle of 16° (FA). In addition, 110 functional images 
(pseudocontinuous arterial spin labeling [ASL] sequence), 
providing 20 slices with 64 × 64 matrix points with a non-
cubic FOV of 230 mm, yielding a nominal isotopic reso-
lution of 4.27 mm3 (ie, 3.6 mm × 3.6 mm × 6 mm) have 
been obtained. Further scan parameters for the functional 
images were TR of 4000 ms, TE of 18 ms, and a FA of 25°.
Structural and perfusion images were processed using 
SPM8 (Wellcome Trust Center for Neuroimaging, London; 
http://www.fil.ion.ucl.ac.uk/spm). Preprocessing of the 
perfusion images was conducted with an in-house-written 
MATLAB program toolbox.29 In detail, ASL images were 
first realigned. From the time series of these realigned 
ASL signal, the mean regional resting-state cerebral blood 
(rCBF) flow was calculated voxelwise and stored as a CBF 
map. Then all these CBS maps were co-registered to the T1 
weighted images, normalized, and smoothed with 8-mm 
full-width at half maximum (FWHM) kernel.
All preprocessing steps of the VBM data were con-
ducted using standard procedures as implemented in 
SPM8 (VBM toolbox). Images were normalized, seg-
mented into tissue classes, modulated, and smoothed 
with 8-mm FWHM kernel.
Statistical Analyses
Statistical tests were performed using SPM routines and 
SPSS 22.0 (SPSS Inc., Chicago, IL, USA). Two-sample t 
tests, 1-way ANOVAs, and chi-square tests (χ2) were used 
to test for group differences in continuous and categorical 
variables. Effects of categorical and continuous variables 
on rCBF and VBM were investigated using whole-brain 
1-way ANCOVAs, 2-sample t tests, and multiple regres-
sion analyses, respectively.
The main focus of the analyses was the effect of cata-
tonia on rCBF. Therefore, rCBF differences were calcu-
lated between all patients, patient subgroups (catatonia 
patients and patients without catatonia), and healthy 
controls using a whole-brain ANCOVA (F and T tests). 
We excluded all voxels with less than 10  ml/min blood 
flow and included age and motion parameters as covari-
ates of no interest.
Within patients, we tested the association of catato-
nia severity and whole-brain rCBF by including BFCRS 
total values and rCBF in a multiple regression analysis 
(T tests). As in the group analyses, we excluded all voxels 
with less than 10 ml/min blood flow and included age and 
motion parameters as covariates of no interest.
Likewise group differences in GM density were cal-
culated comparing VBM between all patients, patient 
subgroups, and controls using a whole-brain ANCOVA 
(F and T tests). Covariates included age and individual 
total GM volumes in order to correct for head size. In 
addition, we excluded all voxels with GM values of less 
than 0.1 (absolute threshold masking). Similarly to rCBF 
data, we tested the association of catatonia severity and 
whole-brain GM density within patients. We therefore 
included BFCRS total values and GM density using mul-
tiple regression analysis (T tests).
A uniform statistical threshold of P <.001 (uncorrected) 
with minimum cluster size of 100 voxels was applied to 
all analyses. For illustration purposes, we extracted the 
data from significant clusters of the whole-brain analyses 
for each subject with the SPM toolbox MarsBaR.38
Exploratory analyses tested the effects of clinical 
parameters on the rCBF findings, including catatonia 
subtypes, medication, parkinsonism, or negative symp-
toms. First, to rule out the putative effects of medica-
tion on our whole-brain findings, we provided additional 
ANCOVAs of the main contrasts in the supplementary 
material with CPZEs and DEs as additional covariates. 
Second, we compared extracted mean perfusion values 
in the SMA cluster between catatonia subtypes (retarded 
type: n = 6 and excited type: n = 9), patients without cata-
tonia, and healthy controls using an ANOVA with post 
hoc T tests corrected for multiple comparisons (Sidak). 
Third, we calculated partial correlations of extracted 
CBF values in patients and catatonia severity (BFCRS) 
controlling for UPDRS III, PANSS negative, CPZEs, 
and DEs.
Results
As expected, scores of catatonia (BFCRS), negative symp-
toms (PANSS negative), and parkinsonism (UPDRS III) 
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were highly correlated (BFCRS and PANSS negative: 
r =  .474, P =  .002; BFCRS and UPDRS III: r =  .655, 
P ≤ .001; PANSS negative and UPDRS III: r  =  .354, 
P =  .021).12,39,40 Furthermore, in line with the literature, 
no catatonia symptom was confined exclusively to 1 cata-
tonia subtype41 (supplementary table S1B and S1C).
SMA Hyperperfusion in Catatonia
Motion parameters of CBF data demonstrated no group 
difference (see supplementary table S2). The ANCOVA 
of rCBF identified significant group effects in the bilat-
eral SMA (P(FWE-corr.) < .001), anterior cingulate cortex 
(ACC, P(FWE-corr.)  =  .014), dorsolateral prefrontal cor-
tex, left interior parietal lobe, left superior temporal 
gyrus (P(FWE-corr.) =  .036), and left ventral premotor cor-
tex (vPMC) comparing patients with catatonia, patients 
without catatonia, and healthy controls (see table 2 and 
figure 1A; supplementary table S3).
The comparison of all schizophrenia patients inde-
pendent of catatonia symptoms and healthy controls (T 
test) revealed several mainly frontal and temporal brain 
areas with reduced rCBF in patients. However, no effect 
appeared in the SMA and the vPMC contrasting all 
patients to controls (table  2 and figure  1B; supplemen-
tary table S3). Instead, subjects with current catatonia 
had significant hyperperfusion in the SMA and the left 
vPMC compared to patients without catatonia (table  2 
and figure 1C; supplementary table S3).
Moreover, within patients, catatonia severity and 
rCBF were linearly associated within the SMA and the 
left vPMC. In fact, severer catatonia was associated with 
higher perfusion of brain regions including bilateral the 
SMA and the left vPMC (supplementary figure S1 and 
table S4).
Furthermore, the ANCOVA of rCBF including antipsy-
chotic and benzodiazepine dosages as covariate (CPZEs 
and DEs) yielded substantially the same results confirming 
relative hyperperfusion of the SMA in catatonia patients vs 
noncatatonic patients (see supplementary table S5).
Among patients, relative hyperperfusion of the SMA 
appears to be specific to catatonia. But the type of catato-
nia presentation had a major influence. Exploratory tests 
of extracted rCBF values in the SMA cluster with sig-
nificant (FWE-corrected) group effect in the ANCOVA 
(catatonia vs patients without catatonia vs healthy con-
trols) substantiate increased rCBF in retarded catatonia 
compared to excited catatonia patients and compared to 
noncatatonic patients (T = 7.102, P = .034 and T = 6.082, 
P < .001) (figure 2B). Moreover, noncatatonic patients had 
reduced rCBF compared to healthy controls (T = 3.340, 
P < .001). A very similar finding emerged for the rCBF 
data extracted from the cluster within the vPMC (see sup-
plementary figure S2).
Exploratory partial correlations indicated that 
extracted rCBF in the SMA and catatonia severity were 
positively correlated (r(40)  =  .514, P  =  .001) in patients. 
This association remained significant when controlling 
for parkinsonism, negative symptoms, and medication 
(r(36) = .366, P = .024) (see supplementary figure S3).
Reduced Insular and Frontal GM Density in Catatonia
A significant group effect in GM density appeared 
in various brain areas, including the right insula 
(P(FWE-corr.)  =  .012) and the frontal and temporal cortex 
Table 2. Resting-State Cerebral Blood Flow in Patients With and Without Catatonia and Controls (Regions Surviving Family-Wise 
Error Correction)
Cluster Peak MNI Coordinates
k P(FWE-corr.) F(2,73)/T(73) x y z
(A) F test: catatonia patients, patients without catatonia, and controls
 L/R SMA 1620 <.001 28.525 4 12 52
 L/R ACC 772 .014 17.779 8 34 14
 L superior temporal gyrus 402 .036 16.192 −40 −30 14
(B) T test: controls > all patients
 L/R primary motor cortex (M1) 118 .022 5.141 0 −16 76
 R superior extending to middle frontal gyrus 526 .041 4.961 28 24 56
(C) T test: catatonia patients > patients without catatonia
 L/R SMA 193 .037 4.991 2 12 50
(D) T test: catatonia patients > controls
 No clusters
(E) T test: patients without catatonia > catatonia patients
 No clusters
(F) T test: controls > catatonia patients
 No clusters
Note: ACC, anterior cingulate cortex; SMA, supplementary motor area. Full table with all significant effects, see supplementary material 
covariates: age, motion parameters.
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(see supplementary figure S4A and table S6A). Patients 
with catatonia had reduced GM density compared to 
controls in frontal cortex and insula, but not in the tem-
poral cortex (supplementary figure S4C and table S6C). 
In contrast, schizophrenia patients without catatonia had 
reduced GM density compared to controls in temporal 
and frontal cortex, but not in the insula (supplementary 
figure S4B and table S6B). In addition, patients with 
catatonia had increased cerebellar GM density compared 
to patients without catatonia in a large cluster including 
the cerebellar region VIIb.
Moreover, catatonia severity demonstrated a positive 
linear association with GM within patients within the cer-
ebellum (supplementary figure S5A and table S7A) and an 
inverse association within the frontal cortex and the insula 
(supplementary figure S5B and table S7B). In fact, severer 
Fig. 1. Cerebral blood flow in patients and healthy controls. (A) Group effect comparing patients with and without catatonia and healthy 
controls. (B) Decreased resting-state cerebral blood flow (rCBF) in patients comparing all patients independent of catatonia symptoms 
and healthy controls. (C) Increased rCBF in the supplementary motor area in patients with catatonia compared to patients without 
catatonia. Covariates: age and motion parameters. 
Fig. 2. (A) Group effect comparing resting-state cerebral blood flow (rCBF) between patients with and without catatonia and healthy 
controls. (B) Mean rCBF values in the supplementary motor area in all in patients with catatonia and motor excitation, in patients with 
retarded catatonia, noncatatonic patients and healthy controls. Values of scores of catatonia severity = 0 in noncatatonic patients and 
healthy controls. BFCRS, Bush Francis Catatonia Rating Scale.
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catatonia was associated with higher GM density of the 
cerebellum and lower GM density of the frontal cortex 
(superior frontal gyrus and ACC) and the right insula.
Finally, the exploratory ANCOVA of GM density 
including antipsychotic and benzodiazepine dosage 
(CPZEs and DEs) as covariates yielded substantially the 
same results confirming reduced GM density compared 
to controls in frontal cortex and insula, but not in the 
temporal cortex in catatonia as well as increased cerebel-
lar GM density compared to noncatatonic patients (see 
supplementary table S8).
Discussion
Even though catatonia is a highly prevalent syndrome,2,3 
the underlying pathobiology is still unknown. The exist-
ing studies investigated small clinically heterogeneous 
samples with very basic measures of rCBF. Here, we 
focused on state catatonia in schizophrenia as deter-
mined by a standard clinical rating scale, ie, the BFCRS. 
Furthermore, we applied a modern rCBF measure, ie, 
MRI with ASL. Indeed, ASL provides an absolute mea-
sure of rCBF, reflecting the level of state neuronal activ-
ity with superior spatial resolution compared to positron 
emission tomography. We confirmed our hypothesis of 
increased resting-state blood flow in premotor areas in 
catatonia compared to noncatatonic patients. In fact, 
among schizophrenia patients, increased perfusion in 
the SMA and vPMC, key regions for self-initiated move-
ments,26,42 was specific for state catatonia. Particularly, 
SMA perfusion differed between excited and retarded 
catatonia, indicating increased SMA neural activity in 
the retarded state. Moreover, increased catatonia severity 
was associated with higher perfusion in SMA and vPMC. 
These findings held true even after controlling for antipsy-
chotic and benzodiazepine dosage. Finally, we detected 
a specific pattern of GM decrease in catatonia patients 
compared to controls, which appeared different from the 
pattern in schizophrenia patients without catatonia.
The SMA as a Key Player
The SMA is tightly connected to the primary motor cor-
tex, the pre-SMA, the striatum (including direct and indi-
rect motor pathways), the subthalamic nucleus (STN) 
(hyperdirect pathway), the thalamus, and the corticospinal 
tract.43 The SMA is involved in selecting, preparing, and 
executing different modes of action, particularly internally 
generated movements.43 Most important, SMA activ-
ity may facilitate or inhibit ongoing action via the basal 
ganglia loops.43,44 Particularly, the hyperdirect pathway 
from SMA to the STN can rapidly stop ongoing move-
ment.45 Aberrant SMA structure and function has been 
implicated in altered motor behavior in schizophrenia. For 
example, structural alterations in the SMA46 and connect-
ing fibers27,29 were associated with the severity of motor 
impairments in schizophrenia. Furthermore, reduced 
SMA activation during motor tasks has been repeatedly 
reported in schizophrenia, in general,47 and in catatonic 
schizophrenia.17,21 Finally, increased rCBF in premotor 
areas, including the SMA, correlated with higher objec-
tively assessed motor activity in schizophrenia.29 Hence, the 
present study adds to existing body of evidence support-
ing a key role of the SMA in psychomotor symptoms in 
schizophrenia. According to our model, patients present-
ing motor symptoms may use cortical pathways involving 
the SMA to compensate for insufficient or inhibitory basal 
ganglia output.26 Indeed, retarded catatonia states pre-
sented with hyperperfusion of the SMA, linking increased 
neural activity to massive motor inhibition. In line with 
this observation, motor retardation in acute catatonia is 
alleviated by lorazepam administration.7 In fact, one study 
demonstrated reduced iomazenil binding in the left senso-
rimotor cortex in akinetic catatonia, suggesting a decrease 
in the density of GABAA receptors in the primary motor 
cortex in patients without benzodiazepine administration 
in the prior 6 months.23 Thus, benzodiazepine effects on 
various neurotransmitter systems may normalize rCBF in 
the motor loop including SMA. However, the molecular 
mechanism underlying catatonic states associated with 
increased SMA perfusion remains to be elucidated.
There are several possible explanations for increased 
rCBF in schizophrenia patients with state catatonia. 
For instance, increased neural activity may results from 
attempts to overcome massive inhibitory basal ganglia 
output. Alternatively, SMA hyperactivity may also drive 
basal ganglia inhibitory effects via the hyperdirect path-
way to the STN.43,45 However, based on our previous 
findings in schizophrenia, we suggest that SMA hyper-
perfusion in catatonia may be related to inefficient con-
nectivity between basal ganglia and cortical motor areas 
probably giving rise to motor inhibition.26–29
Studies in other neuropsychiatric disorders with 
reduced motor behavior point in a similar direction. 
Bradykinesia in Parkinson’s disease (PD) shares some 
of the abnormal motor behavior of catatonia.2 In PD, 
the balance within the corticobasal ganglia motor loop 
is shifted to hypoactivation of the motor and premotor 
cortices,48 based on diminished drive within basalganglia-
thalamo-premotor circuits. Specifically, older functional 
MRI literature suggests that bradykinesia is related to 
hypoactivation of SMA, which is thought to be partially 
compensated by hyperactivation of the primary motor 
cortex,49 pointing to a dysbalance within premotor-motor 
networks. In line with our finding, abnormally increased 
metabolic activity was detected in the motor network (par-
ticularly the premotor and motor cortex) of PD patients 
at rest.50 Likewise, major depressive disorder frequently 
presents with psychomotor retardation. In patients with 
major depressive disorder, we detected increased perfu-
sion of SMA with reduced motor behavior, an associa-
tion that was paralleled in controls at trend level.51 As in 
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retarded catatonia, behavioral inhibition was associated 
with increased SMA perfusion.
Structural Changes Linked to Catatonia
In line with the literature, schizophrenia was associated 
with reduced GM density in the bilateral insula, the ante-
rior cingulate gyrus, and the left inferior frontal cortex.52 In 
addition, the pattern of relative GM density reductions dif-
fered between patients with catatonia and patients without 
catatonia. In fact, while temporal GM density was reduced 
in patients without catatonia symptoms compared to con-
trols, this was not the case in the comparison of catatonia 
vs controls. A prominent loss of right hemispheric insu-
lar GM density was exclusively seen in catatonia patients 
compared to controls, along with frontal (eg, ACC) GM 
reductions. Finally, patients with catatonia had increased 
cerebellar GM density compared to patients without cata-
tonia in a large cluster including the cerebellar region VIIb. 
This posterior cerebellar subregion has effective motor 
output on many body regions, most prominently the upper 
and lower extremities.53,54 Region VIIb sends output to 
striatal neurons of the indirect pathway.55 Furthermore, 
region VIIb has efferents to the motor part of the STN, 
which in turn is connected to SMA and M1.55 As noted 
above, STN is a key node of the indirect and the hyperdi-
rect pathway within the motor corticobasal ganglia circuit. 
Aberrant increased STN activity would result in reduced 
motor output, as seen in PD.55 Therefore, increased GM 
of area VIIb may well fit in the hypothesis of inhibitory 
basal ganglia action in catatonia.26 In addition, this finding 
points towards a pathology in pathways including the STN 
in catatonia. Again, whether it is a direct inhibitory effect 
via motor cortex and STN or a compensation of inefficient 
connectivity within the corticobasal ganglia loop remains 
to be discovered. Some authors have suggested that cor-
tico-cerebellar motor loops may compensate inhibition of 
the corticobasal ganglia loop in PD.48 This could also be 
the case in schizophrenia-associated catatonia. The GM 
density results held true after correction for antipsychotic 
and benzodiazepine dosage. Furthermore, our findings are 
in line with the few available structural neuroimaging stud-
ies showing prominent frontal as well as cerebellar struc-
tural changes linked to the catatonia syndrome.24,25
Clinical Heterogeneity in Catatonia
Distinct types of catatonia have been proposed, as the 
clinical presentation of catatonia is characterized by 
multiple symptoms and varying course among patients. 
Interestingly, 2 classical catatonia types,7 differed in rest-
ing-state SMA perfusion: hyperperfusion in the retarded 
type and hypoperfusion in the excited type. The 2 types 
have been repeatedly identified in factor analyses4,10 and 
are considered to be opposing behavioral presentations. 
Our data suggest distinct pathobiology of the 2 subtypes 
within the same syndrome. Retarded catatonia includes 
symptoms such as stupor, mutism, rigidity, and negativ-
ism. Instead, the excited type is characterized by excite-
ment, grimacing, stereotypy, and verbigeration.10 The 
SMA and related medial premotor areas, such as the cin-
gulate motor area and pre-SMA, have been implicated 
in volitional aspects of behavior and drive.2,26,43 Most of 
the catatonia symptoms refer to disturbances in volition, 
action selection or motor planning.2
This dissociation between excited and retarded catato-
nia may also explain the inconsistencies in brain imaging 
studies with cerebral hypoperfusion as well as hyperper-
fusion in catatonia. Moreover, our results suggest that 
different catatonia states have distinct pathobiology. 
In addition, the results on excited and retarded catato-
nia require careful interpretation, given the exploratory 
nature of such kind of analysis and the small sample size 
of these catatonia subtypes.
The diagnosis and nosology of the catatonia syndrome 
remains a matter of debate. There are probably more 
than the investigated 2 classic catatonia dimensions. In 
fact, factor analytic studies identified 3–6 factors.4,10,56–59 
The ongoing debate on the definition and course of 
catatonia, however, hampers thorough neurobiological 
investigations.4,60
Currently, there is no evidence supporting a differential 
treatment of catatonia subtypes in schizophrenia. Some 
clinical characteristics have been suggested to influence 
treatment response to electroconvulsive therapy (ECT) or 
benzodiazepines, among them chronicity, predominant 
affective state, age, and schizophrenia diagnosis.61–63 Case 
series reported rapid response to benzodiazepine admin-
istration in patients with acute stupor.64,65 Moreover, 
some experts suggested effectiveness of benzodiaze-
pines in retarded catatonia.61 In contrast, a randomized 
placebo-controlled trial failed to demonstrate an effect 
of lorazepam on catatonia in chronic schizophrenia.62 
Both catatonia subtypes (retarded and excited type) in 
nonaffective psychoses benefit from antipsychotic ther-
apy.9 To our knowledge, no randomized controlled trial 
investigated the impact of catatonia subtypes on treat-
ment response to ECT or benzodiazepines in schizophre-
nia. We may speculate that increased SMA perfusion in 
retarded catatonia could be reduced by benzodiazepine 
administration alleviating the motor inhibition; however, 
this has to be tested in future studies.
Possible Limitations
First of all, this study exclusively focused on catatonia in 
the context of schizophrenia spectrum disorders. Thus, 
our results must not be easily transferred to catatonia 
of different origin. In addition, patients requiring ECT 
were excluded. Patients with substantial negativism were 
not included if  they could not provide informed consent. 
These limitations introduce some selection bias.
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Furthermore, all patients with catatonia had received 
treatment for the catatonic syndrome. In fact, medication 
with antipsychotics and benzodiazepines remains one 
possible limitation of our study as all but 3 patients were 
medicated with antipsychotics and 6 patients received 
benzodiazepines, which may affect brain structure and 
function. However, reanalyzing our data including dos-
age of antipsychotics and benzodiazepines as covariates 
yielded substantially the same results. As expected, cata-
tonia patients had more parkinsonian signs and nega-
tive symptoms compared to patients without catatonia. 
However, partial correlations indicated higher SMA perfu-
sion associated with catatonia severity even when control-
ling for parkinsonism, negative symptoms, and medication 
dosage. In line with the literature, catatonia, parkinson-
ism, and negative symptoms are highly correlated in our 
sample.12,39,40,66 This might either reflect true comorbidity 
or more likely constitute a “conflict of paradigms,” ie, con-
ceptual overlap when observing the same phenomenon 
as proposed by Rogers.67 Finally, a relatively small number 
of patients has been included in our analysis and explor-
atory analyses of catatonia subtypes have therefore to be 
interpreted with caution. However, to our knowledge, this 
is the largest homogeneous group of catatonia patients 
ever investigated with brain imaging.
Conclusions
SMA resting-state perfusion may serve as a marker of 
current catatonia in schizophrenia. This is highly com-
patible with a dysregulated motor system in catatonia, 
particularly affecting premotor areas and the STN. 
Furthermore, differentially altered SMA perfusion was 
shown in retarded and excited catatonia arguing for bio-
logically distinct clinical subtypes. Further studies need 
to clarify whether the findings also hold true for catato-
nia of different origin. The distinct clinical and biological 
subtypes of catatonia may require different therapeutic 
approaches, which remain to be discovered.
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Supplementary material is available at http://schizophre-
niabulletin.oxfordjournals.org.
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